One Supplier Deep: The ADC Industry's Payload Problem

The ADC story everyone tells is a story about antibodies. New targets, better selectivity, the next generation of binders. The capital follows that story, and so do the headlines about conjugation suites and one-stop CDMO platforms.

The thing that actually stops an ADC programme is none of those. It is the small molecule bolted onto the antibody, and the few companies in the world that can make it to specification.

The part of the stack nobody guards

An ADC is three things stacked on top of each other: an antibody, a linker, and a cytotoxic payload. The antibody gets the science budget and the board's attention. The conjugation step gets the capacity announcements. The payload and the linker get treated as a reagent line on a bill of materials.

That is a category error. The payload is the load-bearing supplier. It is the one input in the stack where there is no quick alternative, no meaningful stockpile, and no way to swap a vendor on a timeline that fits a clinical plan.

Pull the antibody supplier and you have a tech transfer. Pull the conjugation site and you have other suites you can qualify into. Pull the payload or the linker-payload and, for most programmes, you have a two-year hole.

How concentrated it actually is

The payload classes carrying the current wave are a short list. Auristatins such as MMAE and MMAF. Maytansinoids such as DM1 and DM4. And, most consequentially, the topoisomerase-I inhibitor camptothecin derivatives, the chemistry behind the Enhertu generation that reset what the market expects an ADC to do.

These are high-potency active pharmaceutical ingredients made under OEB-5 containment by a small set of specialist contract manufacturers. A meaningful share of payload synthesis, linker-payload assembly, and the precursor chemistry that feeds them sits in China. WuXi and its peers became central to the field precisely because the Western HPAPI base could not absorb the demand fast enough.

So you have a wide, fast-growing front end, more than 1,200 active ADC molecules in development globally, narrowing down to a thin and geographically concentrated back end. That is a constraint funnel: a lot of programmes pouring into a narrow throat, and the throat is held by a handful of suppliers.

Why the topoisomerase-I crowd makes it worse

The single-supplier risk would be manageable if demand were spread evenly across chemistries. It is not.

There are close to 100 topoisomerase-I inhibitor ADCs in development, almost all of them leaning on a narrow band of camptothecin-derivative payload chemistry and the few manufacturers capable of producing it at clinical and commercial scale. When one chemistry class becomes the consensus bet, the supply base under it does not widen at the same rate. It saturates.

The result is that programmes which look differentiated at the antibody level are often undifferentiated at the payload level. They are all standing in the same queue, for the same chemistry, behind the same suppliers.

BIOSECURE turned a sourcing question into a board question

For years, single-source payload supply was a procurement footnote. The BIOSECURE legislative effort in the United States moved it onto the risk register.

Whatever its final legislative fate, the proposal to restrict federal-adjacent business with named Chinese providers has already changed sourcing behaviour. Sponsors that had a single qualified payload route are now being asked, by their own boards and by diligence teams, what happens if that route closes. The honest answer, for many, is that they do not have a second one ready.

And building one is not fast.

The requalification clock is the real exposure

Moving a payload or a linker-payload to an alternative site is not a purchase-order change. It is a comparability exercise on a high-potency, often chiral, synthesis with tightly controlled impurity and genotoxicity profiles.

Requalifying that chemistry at an ex-China facility runs to roughly 18 to 24 months before you factor in regulatory comparability filings. There is no stockpile that solves a two-year gap, because the constraint is qualification time, not warehouse space. A sponsor that starts dual-sourcing the day the risk becomes acute is already two years late.

That is what makes the payload a single point of failure rather than an ordinary supply risk. The exposure is not the price of the material. It is the lead time to replace it.

What it means, by seat

The exposure reads differently depending on where you sit.

For drug developers, a single-source payload is an undisclosed clause in your launch plan. It deserves the same diligence as a clinical risk, not a line in the appendix. The programmes that come through cleanly will be the ones that qualified a second route before they needed it, on the same logic that good operators secure isotope and sterile capacity ahead of demand.

For investors, two otherwise identical ADC assets are not equal if one has a dual-sourced, requalified payload chain and the other is one supplier deep. The supply chain belongs in the valuation. A pipeline built on consensus camptothecin chemistry carries a correlated risk that asset-by-asset models miss.

For CDMOs and integrators, the differentiator is shifting. Conjugation capacity is being built everywhere. Secured, qualified payload and linker-payload supply is not. The platforms that win the next cycle will be the ones that can guarantee the back end of the stack, not just the middle.

The hire nobody is mapping

There is a leadership consequence that sits underneath all of this, and the market has not priced it either.

De-risking a payload chain needs a leader who is fluent in three languages at once: HPAPI process chemistry, analytical comparability, and supply geopolitics. Someone who sits between CMC, external manufacturing, procurement and regulatory, and who can run a second-source qualification as a programme rather than a panic.

That profile is rare. It is not produced cleanly by any single career track, because the people who understand the chemistry usually do not own the supplier relationship, and the people who own the relationship usually cannot read the comparability data. Whether a programme actually has a credible second source, rather than a slide that claims one, often comes down to whether that person is in the building.

What this does not cover, and where it could be wrong

A few honest boundaries.

Western HPAPI capacity is being built, and several established players are expanding payload and linker capability outside China. The concentration is real today; it is not permanent. Not every payload class is equally exposed, and some sponsors, particularly the larger ones, already dual-sourced years ago and are sitting comfortably. The constraint also eases as the camptothecin crowd thins out and programmes fail or differentiate onto other chemistries.

None of that changes the direction of travel. For the next development cycle, the scarce, slow-to-replace input in an ADC is the small molecule and the handful of people who can make it to spec.

The takeaway

The ADC boom has been financed and narrated as an antibody story. The execution risk that decides which programmes reach patients is a small-molecule story, and a supply-chain one.

The operators who come through this will be the ones who treated the payload as part of the asset rather than a reagent line, who qualified a second route before the risk forced their hand, and who found the person who could run that qualification long before they needed one. The rest will discover, somewhere around their PPQ batches, that the most important supplier in the building was the one nobody was guarding.

If you are stress-testing your payload exposure, or working out who could actually run a second-source qualification, that is the work we do. The full map of who makes what, where, and how exposed each payload class is sits in our State of ADCs 2026.

ProGen Search runs retained executive search and market intelligence across ADC, CDMO, radiopharma and advanced modalities. This article is provided for information only and is not investment, legal or regulatory advice. Supplier concentration, legislative status and qualification timelines reflect the state of play as of Q2 2026 and may have changed since publication.